Hester BiosciencesBOM:524669 +1.48%73 EBITDA Margin % is 36.06% as of Mar. 2026, which is 14% above its 10-year median of 31.67. GuruFocus rates BOM:524669 with a GF Score™ of 73/100 and a GF Value™ of ₹1,885.73 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Hester Biosciences ranks better than 88.78% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hester Biosciences's EBITDA for the
three
months ended in Mar. 2026 was ₹361 Mil. Hester Biosciences's Revenue for the
three
months ended in Mar. 2026 was ₹1,001 Mil. Therefore, Hester Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was 36.06%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hester Biosciences EBITDA Margin % Related Terms
Hester Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hester Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524669 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hester Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hester Biosciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hester Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hester Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hester Biosciences (BOM:524669) has a EBITDA Margin % of 36.06% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hester Biosciences and its competitors. This is 14% above median its historical median of 31.67. Over the past decade, Hester Biosciences' EBITDA Margin % has ranged from 19.13 to 41.51. According to the industry distribution chart, Hester Biosciences ranks #107 out of 954 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is Hester Biosciences' EBITDA Margin % too high?
Hester Biosciences' current EBITDA Margin % of 36.06% is 14% above median its 10-year median of 31.67. Over the past 10 years, this metric has ranged from a low of 19.13 to a high of 41.51. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Hester Biosciences' value of 36.06% is 188.1% above this industry median. Based on the distribution chart, Hester Biosciences ranks #107 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hester Biosciences has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hester Biosciences' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hester Biosciences ranks #107 out of 954 companies for EBITDA Margin %. This places Hester Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Hester Biosciences' value of 36.06% is 188.1% above this benchmark. Historically, Hester Biosciences' own EBITDA Margin % has ranged from 19.13 to 41.51 over the past decade. While the company's 10-year median is 31.67 vs. the industry median of 12.52, Hester Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hester Biosciences's current EBITDA Margin % of 36.06% is 188.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hester Biosciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hester Biosciences's current EBITDA Margin % is 36.06%, which is 14% above median its own 10-year median of 31.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hester Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Hester Biosciences (BOM:524669) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,885.73, compared to a current price of ₹2,193.45 — trading 16.3% above its estimated fair value. The current EBITDA Margin % is 36.06%, which is 14% above median its 10-year median of 31.67 and 188.1% above the Drug Manufacturers industry median of 12.52. Hester Biosciences' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hester Biosciences (BOM:524669), the current EBITDA Margin % is 36.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hester Biosciences (BOM:524669) Overvalued in 2026?
Based on GuruFocus' analysis, Hester Biosciences stock appears to be overvalued.
The current stock price of ₹2,193.45 is trading 16.3% above its estimated GF Value™ of ₹1,885.73.
GuruFocus considers Hester Biosciences to be Modestly Overvalued.
Key valuation signals for BOM:524669:
EBITDA Margin %: 36.06% (14% above median its 10-year median of 31.67)
GF Value™: ₹1,885.73 vs. price of ₹2,193.45 (16.3% above fair value)
Industry Position: 188.1% above the Drug Manufacturers median (#107 of 954)
No single metric tells the full story. See the BOM:524669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hester Biosciences Ltd is an India-based animal healthcare company. It is principally engaged in the manufacturing of veterinary vaccines and trading of veterinary health products such as goat pox vaccine, PPR vaccines, etc. The group has two principal operating and reporting segments, viz. Poultry healthcare and Animal healthcare. Maximum revenue is generated from the Poultry Healthcare segment, which offers various solutions encompassing vaccines, health products, and feed supplements, supported and packaged by its diagnostic services, R&D, quality standards, and field support, to help farmers protect flock health, enhance productivity, and drive long-term farm sustainability. Geographically, it generates maximum revenue within India, and also exports its products to other markets.
73GF Score
Get the complete analysis for BOM:524669
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524669 has been successfully added to your 
